Top payer group shoots down Gilead's hep C drug Sovaldi on price

Gilead's Sovaldi--Courtesy of Gilead

Individual payers aren't alone in balking at the $84,000 price for Gilead Sciences' ($GILD) new hepatitis C treatment Sovaldi. Now, the leading insurance trade group has joined the soloists, backing their complaints with its own. Report

Read more on